C5 and myasthenia gravis: Although no interaction with commonly administered MG medications was anticipated, it was notable that despite a high proportion of patients receiving concomitant medications for MG, there were no unexpected findings with respect to either serum ravulizumab or serum free C5 concentrations and all patients achieved serum free C5 concentrations below the target threshold.